Paper Details

  1. Home
  2. Paper Details

Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.

Author: Antonio CasadoJosé, ArangoDiego, BuerenJuan A, Carrascoso-RubioCarlos, Carreras-PuigvertJordi, GonzálezAlan, HelledayThomas, LasaAdriana, LermaEnrique, Martínez-BarriocanalÁgueda, MinguillónJordi, MontanuyHelena, NietoRocío, RamírezMaria José, RieraPau, RovirosaLlorenç, SurrallésJordi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explored potential new therapies for head and neck squamous cell carcinoma in Fanconi anemia patients. Two currently approved drugs were identified as possible treatment options.
Paper Details　
Original Abstract of the Article :
Fanconi anemia rare disease is characterized by bone marrow failure and a high predisposition to solid tumors, especially head and neck squamous cell carcinoma (HNSCC). Patients with Fanconi anemia with HNSCC are not eligible for conventional therapies due to high toxicity in healthy cells, predomin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-19-1625

データ提供：米国国立医学図書館（NLM）

Novel Therapies for Fanconi Anemia-Related Head and Neck Cancer

This study investigates the potential of [gefitinib and afatinib] as new therapies for [Fanconi anemia-related head and neck squamous cell carcinoma (HNSCC)]. The researchers highlight the challenges of treating [HNSCC] in [Fanconi anemia] patients due to the high toxicity of conventional therapies. They suggest that [gefitinib and afatinib] could offer a safer and more effective alternative.

Expanding Treatment Options for Fanconi Anemia Patients

This study offers hope for individuals with [Fanconi anemia] who are diagnosed with [HNSCC]. The researchers' findings provide a foundation for further research into the use of [gefitinib and afatinib] as potential therapies.

Improving Treatment Outcomes for Rare Diseases

This study underscores the need for innovative treatment approaches for [rare diseases] like [Fanconi anemia]. The researchers' exploration of novel therapies highlights the importance of ongoing research to improve treatment options and enhance the lives of individuals living with [rare diseases].

Dr.Camel's Conclusion

This study delves into the challenging world of treating [Fanconi anemia-related HNSCC], exploring the potential of [gefitinib and afatinib]. Like a camel seeking out hidden oases, this research ventures into new territories, offering hope for a better future for individuals with [Fanconi anemia].

Date :
  1. Date Completed 2021-09-13
  2. Date Revised 2021-09-13
Further Info :

Pubmed ID

32005748

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-19-1625

Related Literature

Article Analysis
・Side Effects of afatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.